Previous Article | Next Article 
Journal of Virology, July 1999, p. 5970-5980, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Replication of Murine Cytomegalovirus in
Differentiated Macrophages as a Determinant of Viral
Pathogenesis
Laura K.
Hanson,1
Jacquelyn S.
Slater,1
Zaruhi
Karabekian,1
Herbert W.
Virgin IV,2
Christine A.
Biron,3
Melanie C.
Ruzek,3
Nico
van
Rooijen,4
Richard P.
Ciavarra,1
Richard M.
Stenberg,1 and
Ann E.
Campbell1,*
Department of Microbiology and Molecular Cell
Biology, Eastern Virginia Medical School, Norfolk, Virginia
235071; Department of Pathology,
Washington University School of Medicine, St. Louis, Missouri
631102; Department of Molecular
Microbiology and Immunology, Brown University, Providence, Rhode Island
029123; and Department of Cell
Biology and Immunology, Free University, Amsterdam, The
Netherlands4
Received 30 November 1998/Accepted 16 April 1999
 |
ABSTRACT |
Blood monocytes or tissue macrophages play a pivotal role in the
pathogenesis of murine cytomegalovirus (MCMV) infection, providing
functions beneficial to both the virus and the host. In vitro and in
vivo studies have indicated that differentiated macrophages support
MCMV replication, are target cells for MCMV infection within tissues,
and harbor latent MCMV DNA. However, this cell type presumably
initiates early, antiviral immune responses as well. In addressing this
paradoxical role of macrophages, we provide evidence that the
proficiency of MCMV replication in macrophages positively correlates
with virulence in vivo. An MCMV mutant from which the open reading
frames M139, M140, and M141 had been deleted (RV10) was defective in
its ability to replicate in macrophages in vitro and was highly
attenuated for growth in vivo. However, depletion of splenic
macrophages significantly enhanced, rather than deterred, replication
of both wild-type (WT) virus and RV10 in the spleen. The ability of
RV10 to replicate in intact or macrophage-depleted spleens was
independent of cytokine production, as this mutant virus was a poor
inducer of cytokines compared to WT virus in both intact organs and
macrophage-depleted organs. Macrophages were, however, a major
contributor to the production of tumor necrosis factor alpha and gamma
interferon in response to WT virus infection. Thus, the data indicate
that tissue macrophages serve a net protective role and may function as
"filters" in protecting other highly permissive cell types from
MCMV infection. The magnitude of virus replication in tissue
macrophages may dictate the amount of virus accessible to the other
cells. Concomitantly, infection of this cell type initiates the
production of antiviral immune responses to guarantee efficient
clearance of acute MCMV infection.
 |
INTRODUCTION |
Blood monocytes and tissue
macrophages play a major role in the pathogenesis of cytomegalovirus
(CMV) infections by serving as target cells in infected organs, as
disseminators of the virus throughout the host, or as sites of CMV
latency (reviewed in reference 32). The prominence
of this cell lineage as a host for human CMV (HCMV) infection and
replication is revealed by the frequent detection of HCMV DNA, RNA, or
antigens in progenitor cells of the monocyte/macrophage lineage, in
peripheral blood monocytes, or in differentiated macrophages infected
in vitro or in vivo with HCMV (8, 18, 22, 25, 29, 31-33, 49, 51,
69). Infected blood monocytes, likely derived from infection of
bone marrow progenitor cells, may disseminate HCMV to other permissive cells of the host (32, 65). The relatively nonpermissive
monocytes and bone marrow progenitor cells harbor latent HCMV DNA
(11, 22, 24), which reactivates upon cellular
differentiation (25, 29, 50, 53, 54, 58).
Mouse studies using murine CMV (MCMV) corroborate findings with humans
by identifying the macrophage as a major target cell. In mouse bone
marrow, MCMV predominates within stromal cells (55), although hematopoietic progenitor cells may also be infected (20, 41). Circulating blood monocytes disseminate MCMV during acute infection, and their subsequent cellular differentiation into mature
macrophages favors productive MCMV replication (2, 4, 16, 17, 34,
56, 66). During acute infection of the spleen, virus localizes to
areas corresponding to marginal-zone macrophages (56). Since
tissue macrophages are in close contact with circulating blood, they
are likely one of the first cell types infected by blood-borne virus.
Furthermore, macrophages serve as reservoirs of latent MCMV infection
(20, 41).
In addition to their role as targets of MCMV infection, macrophages are
important in the early inflammatory and innate immune responses to
infection. Activated macrophages infiltrate the site of MCMV infection
(17), where they may initiate a cascade of antiviral
cytokines. Initially, the cytokines alpha/beta interferon (IFN-
/
), tumor necrosis factor alpha (TNF-
), interleukin
(IL)-1 alpha, IL-6, and IL-12 are produced in response to early MCMV infection (14, 15, 17, 36, 37, 46, 66, 68). The former two
cytokines have direct antiviral activity in that they inhibit MCMV
replication (10, 17, 28, 40, 66). In addition, IFN-
/
enhances NK-cell-mediated blastogenesis and cytotoxicity, while TNF-
augments IFN-
produced by NK cells (37). IL-12 also
activates NK cells to produce IFN-
, which directly inhibits MCMV
replication (10, 28, 36-38). These two cytokines, IL-12 and
IFN-
, may also cooperate in activating cytotoxic T lymphocytes, which are pivotal in the subsequent clearing of MCMV from most target
organs (23). The role of macrophages in initiating this cascade of cytokine-mediated antiviral activities has not been determined.
Macrophages therefore appear to have dual, even paradoxical, roles: one
as hosts for CMV replication and another as inducers of antiviral
cytokines. Growth of HCMV and MCMV in macrophages is somewhat
restricted, with virus production being delayed (9) or
curtailed (17, 66) compared to infection in fibroblasts. Thus, tissue macrophages may serve as an anatomical and/or functional "filter" in intrinsically or extrinsically protecting other,
more-permissive cell types. We hypothesized that the magnitude of virus
replication in tissue macrophages dictates the amount of virus
accessible to other, more-permissive cells. Concomitantly, infection of
macrophages likely initiates the production of antiviral immune
responses to guarantee efficient clearance of acute infection, thereby
sparing from death the host that serves as a reservoir of latent infection.
With respect to the above hypotheses, we addressed the following
questions. (i) Does the ability of MCMV to replicate in macrophages influence virulence and virus titers in target organs? (ii) Does the
absence of tissue macrophages enhance or deter virus replication in the
spleen and liver, two major target organs for MCMV replication? (iii)
What contributions do macrophages make to the production of early,
antiviral cytokines? Our approach utilized a deletion mutant of MCMV
which was defective for replication in mature macrophages. The highly
attenuated phenotype of this mutant virus in vivo indicated that the
capacity of MCMV to replicate in differentiated macrophages was a major
determinant of virus virulence. However, in the absence of splenic
macrophages, growth of the mutant virus in this organ was restored and
replication of wild-type (WT) virus was enhanced. The induction of at
least two antiviral cytokines, TNF-
and IFN-
, required the
presence of tissue macrophages and was influenced by the capacity of
MCMV to replicate in this cell type. Therefore, while tissue
macrophages support MCMV replication, they exert a net protective role
in the pathogenesis of MCMV infection.
 |
MATERIALS AND METHODS |
Mice.
Six-week-old BALB/cAnN (Harlan Sprague Dawley,
Indianapolis, Ind.) or C57BL/6J (Jackson Laboratories, Bar Harbor,
Maine) mice were housed in sterile microisolator cages with sterile
food, water, and bedding. CB17 severe combined immunodeficient (SCID) mice were bred and housed as previously described (17). Both BALB/cAnN and CB17 mice are of the H-2d
haplotype; C57BL/6 mice are of the H-2b haplotype.
Cells.
Murine NIH 3T3 fibroblasts (ATCC CRL-1658) (American
Type Culture Collection, Rockville, Md.) were propagated in Dulbecco's modified essential medium (Mediatech, Herndon, Va.) supplemented with
10% heat-inactivated bovine calf serum (Hyclone Laboratories, Logan,
Utah) and 1% L-glutamine (Gibco/BRL, Grand Island, N.Y.). IC-21 cells, a simian virus 40-transformed, C57BL/6 mouse peritoneal macrophage line (30) (ATCC TIB 186), were propagated in RPMI medium (Mediatech) supplemented with 10% heat-inactivated fetal calf
serum (Gibco/BRL) and 1% L-glutamine.
Adherent peritoneal exudate cells, providing monolayers of primary
macrophages, were obtained by peritoneal lavage of C57BL/6J mice. Mice
received 10 µg of lipopolysaccharide (LPS) (Difco Laboratories, Detroit, Mich.) intraperitoneally (i.p.) 72 h prior to harvesting of the peritoneal exudate cells. Exudate cells were plated at 3 × 105 to 12 × 105 cells per 10 cm2 in wells or flasks containing Iscove's medium
(Mediatech) supplemented with 10% heat-inactivated fetal calf serum,
1% L-glutamine, and 50 µg of gentamicin/ml (Sigma
Chemical Co., St. Louis, Mo.). After an overnight incubation,
nonadherent cells were vigorously washed from the adherent monolayers.
Adherent cells obtained in this manner had the morphological appearance
of macrophages and were phagocytic, as determined by ingestion of latex
beads (Difco Bacto latex beads; Difco Laboratories). Adherent cells
from representative wells were harvested for counting, and based on
this number, the remaining monolayers were infected at a multiplicity
of 0.1 or 0.5 PFU of MCMV/cell.
Viruses.
The parental WT virus used in these studies was the
MCMV Smith strain (ATCC VR 194). The generation of mutant MCMV RV6,
with open reading frames (ORFs) m137 and m138 deleted, was described previously (2). Mutant MCMV RV10, with ORFs M139, M140, and M141 deleted, with was generated by homologous recombination, using by
our previously described methods (2). A pGEM-4Z
recombination plasmid containing the first (left) two SstI
fragments of MCMV HindIII-J, an e1-
-glucuronidase
(
-Glu) cassette (
-glucuronidase reporter gene under the control
of the MCMV e1 promoter), and the second SstI fragment
within HindIII-I was constructed (pJI
glu-10) (Fig.
1). The pJI
glu-10 recombination
plasmid was cotransfected with WT viral DNA to generate an MCMV mutant
lacking 4.8 kb corresponding to ORFs M139, M140, and M141 (bases 193984 through 198832) (43). Revertant virus, RV10Rev, was produced
by homologous recombination by using infectious, RV10 parental DNA and
a recombination plasmid (pDJI) containing WT sequence from base 191764 (within m137) to base 201966 (within m143) (Fig. 1). Transfections were
performed by using calcium phosphate precipitation as described
previously (2). Virus RV10 was selected based on its blue
plaque phenotype and was plaque purified five times. Virus RV10Rev was
selected based on its white plaque phenotype as described elsewhere
(21). The genotypes of the recombinant viruses were
confirmed by Southern blot analyses. A genetic map of the mutant
viruses is shown in Fig. 1. All virus stocks were prepared in NIH 3T3
cells and quantitated by standard plaque assay on NIH 3T3 cells. Mock
virus preparations were supernatants from uninfected NIH 3T3 cells.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 1.
Construction of the MCMV mutants RV10 and RV10Rev. The
open boxes indicate wild-type MCMV sequences within the
HindIII J and I fragments. Solid lines denote deleted
sequences. Shaded boxes indicate the locations of the
e1- -glucuronidase cassette. Plasmid pJI glu-10 contains MCMV and
e1- -glucuronidase sequences in the vector pGem4Z; pDJI contains the
denoted MCMV sequences in the vector pcDNA3. The numbers refer to sizes
(in kilobases) of the indicated fragments.
|
|
Virion purification by gradient centrifugation.
In some
experiments, gradient-purified virus was used to infect fibroblasts or
IC-21 macrophages. MCMV was purified by gradient centrifugation on a 20 to 70% sorbitol gradient according to published protocols
(5). Briefly, stock preparations of MCMV grown in NIH 3T3
cells were harvested and cellular debris was removed by centrifugation.
Bacitracin (Calbiochem, La Jolla, Calif.) was added to the clarified
supernatant to a final concentration of 100 µg/ml. The
virus-containing supernatant was layered over a cushion of 20%
sorbitol in Tris-buffered saline (TBS) (150 mM Tris, 30 mM NaCl [pH
7.5]) containing bacitracin (100 µg/ml) and then centrifuged at
26,000 × g for 1 h at 18°C. The pelleted virus was resuspended in 2 ml of TBS-bacitracin, layered onto a 20 to 70%
sorbitol gradient, and centrifuged at 65,000 × g for
1 h. Low-density virions banding at the 40 to 50% interface or at
the 50 to 60% interface were harvested, diluted 1:10 in
TBS-bacitracin, and pelleted over a 20% sorbitol cushion for 1 h
at 26,000 × g. The virus was resuspended in
TBS-bacitracin and frozen, and titers were determined by standard
plaque assay.
Southern blot analysis.
Southern blots were used to confirm
the genomic alterations of each viral mutant. Two million NIH 3T3 cells
in 100-mm-diameter tissue culture plates were infected with virus at a
multiplicity of 2 PFU/ml. When the cytopathic effect reached 100%, DNA
was harvested for Southern blot analysis, which was performed as
described previously (2).
Northern blot analysis.
Northern blot analyses of viral RNA
transcripts from RV10-, RV10Rev-, or WT virus-infected cells were
performed essentially as described previously (2). For
analysis of transcripts from the HindIII-J and -I
regions, NIH 3T3 cells were infected at a multiplicity of 2 PFU/cell
for 24 h. For analysis of immediate-early RNAs transcribed from
HindIII-L or HindIII-I, 2 × 106 NIH 3T3 fibroblasts or IC-21 macrophages were infected
at a multiplicity of 1 PFU/cell with virions banding at the 40 to 50%
or 50 to 60% sorbitol interface. After 2 h of adsorption and
penetration, virus inocula were removed, medium was added, and
infection was allowed to proceed for an additional z h. Total RNA was
harvested by using the RNeasy kit (Qiagen, Chatsworth, Calif.)
according to the manufacturer's instructions. Samples containing a
total of 5 µg of RNA, extracted from equal numbers of cells, were
loaded in each lane of a formaldehyde- agarose gel. The loading of
equal amounts of RNA was confirmed by ethidium bromide staining of 18S
and 28S rRNA. RNAs were first hybridized with the MCMV
HindIII L fragment to detect ie1, ie2, and ie3
transcripts. The blot was then stripped by boiling for 10 min in 0.1%
sodium dodecyl sulfate and hybridized with an SstI fragment
from HindIII I (bases 198832 to 201744) to probe for expression of the immediate-early genes m142 and m143. Probes were
labeled with digoxigenin by random priming for detection by chemiluminescence.
In vitro growth of MCMV mutants in fibroblasts and
macrophages.
Mutant and WT MCMV were compared for their abilities
to replicate in fibroblast and macrophage cell lines and in primary, LPS-induced peritoneal macrophages. Approximately 106 NIH
3T3 fibroblasts or IC-21 macrophages in T-25 flasks or 105
primary macrophages in 6-well plates or T-25 flasks were infected at a
multiplicity of 0.1 PFU/cell (cell lines) or 0.1 to 0.5 PFU/cell (primary macrophages). At the indicated times postinfection, both intracellular virus and extracellular virus were harvested collectively and their titers were determined on NIH 3T3 cells. Growth of each virus
in the three cell types was quantitated at least twice.
Southern blot analysis of cell-associated virus.
The mutant
virus RV10 was compared to RV10Rev for its ability to bind to and/or
penetrate IC-21 macrophages. A standard assay for herpesvirus
penetration into cells (27) was modified to account for the
fact that MCMV produces no cytopathic effects in IC-21 macrophages and
consequently does not form plaques in this cell type. Therefore, in
order to detect virus bound to or penetrated into macrophages, Southern
blotting was used to detect viral genomic DNA. Initially, the validity
of this method was tested by using infection of NIH 3T3 fibroblasts to
compare results of the standard penetration assay, which assesses
plaque formation, with those of Southern blotting for viral DNA. For
the former assay, the published procedure was used (27).
Briefly, 106 NIH 3T3 cells in 100-mm-diameter dishes were
infected with WT virus at a multiplicity of 0.0005 PFU/cell (to yield
200 PFU/dish) at room temperature for 1 h. The virus inocula were
then removed, the monolayers were washed with phosphate-buffered saline
(PBS), complete medium was added to each dish, and the temperature of the dishes was shifted to 37°C for the indicated periods to allow attached virus to penetrate. The monolayers of infected cells were
treated with acid-glycine saline (0.8% NaCl, 0.038% KCl, 0.01%
MgCl2, 0.01% CaCl2, 0.7% glycine [pH 3])
for 1 min at 0, 15, 30, 60, 90, or 120 min after shifting to 37°C in
order to inactivate and/or remove low-affinity-bound virus that was
attached but had not yet penetrated. Infected monolayers were then
overlaid with semisolid medium to determine the number of plaques
formed in each treatment group. The percentage of bound virus which
penetrated was calculated as follows: (number of plaques formed on
acid-glycine-washed monolayers)/(number of plaques formed on unwashed
monolayers) × 100.
For the Southern blotting method, fibroblasts or IC-21 macrophages were
infected at room temperature or at 4°C at a multiplicity of 4 PFU/cell for 1 h. Monolayers were washed with PBS to remove the
inocula, and complete medium was added to each dish. After the
temperature shift to 37°C and acid-glycine washes at the indicated times, all infected monolayers were incubated for a total of 4 h.
Cell-associated DNA was harvested and digested with
HindIII and BamHI (Promega, Madison, Wis.)
for Southern blotting to detect viral DNA, performed as described
previously (2). The control for a maximal amount of viral
DNA consisted of infected cells incubated for the entire 4 h
without acid-glycine washing of the monolayers. An MCMV
HindIII-I region probe was used to detect viral DNA.
In vivo growth of MCMV mutants.
Recombinant and WT viruses
were compared for their abilities to replicate in mouse spleen and
liver tissues. Mice received 3 × 105 PFU of tissue
culture-passaged virus intravenously (i.v.) in the tail vein, and
organs were harvested from three individual mice as 20% (wt/vol)
homogenates on each of days 1, 2, and 3 postinfection and titered as
described previously (2). Blood was also collected, in
heparinized tubes, and serial 10-fold dilutions of whole blood in
tissue culture media were used for virus titration. These experiments were performed at least twice.
For assessment of relative virulence, recombinant and WT viruses were
compared for their lethalities for adult (6-week-old) SCID mice. The
SCID mice were injected i.p. with 104 PFU of tissue
culture-passaged mutant or WT virus and observed daily for survival.
Lethality experiments were performed at least twice for each virus.
Macrophage depletion.
Replication of recombinants and WT
viruses was compared in intact and macrophage-depleted spleens and
livers of BALB/cAnN mice. Anesthetized animals were injected i.v. with
a total volume of 0.5 ml containing 300 µl of PBS and 200 µl of
multilamellar liposomes encapsulating dichloromethylene-bisphosphonate
(Cl2MBP) or, as a control, with 0.5 ml of PBS alone. The
Cl2MBP was a kind gift from Boehringer GmbH (Mannheim,
Germany). When liposomes encapsulating Cl2MBP
(L-Cl2MBP) are administered i.v., they are readily
phagocytized by liver macrophages (Kupffer cells) and splenic red pulp
macrophages, marginal-zone macrophages, marginal metallophilic
macrophages, and marginal-zone dendritic cells (26, 35, 63,
64). Lysosomal enzymes present specifically within these cell
populations degrade the liposomes and release the Cl2MBP, leading to apoptosis of the cells (62). Peripheral blood
monocytes and other tissue macrophages (including peritoneal cells) are spared from L-Cl2MBP-induced death when the liposomes are
administered i.v. For this study, use of PBS as a control for
L-Cl2MBP treatment was preferred over use of empty
liposomes, which may alter macrophage functions, including antiviral
activities, in otherwise intact cells (63). The
L-Cl2MBP method of tissue macrophage depletion efficiently
and specifically depletes tissues of macrophages and macrophage-like
marginal dendritic cells without toxicity for other cell types
(61, 63).
Forty-eight hours after L-Cl2MBP administration, mice
received 3 × 105 PFU of tissue culture-passaged WT,
RV10, or RV10Rev virus i.v. The spleen, liver, and blood of four or
five individual mice in each of the two treatment groups were harvested
at 1, 2, or 3 days postinfection for virus titration. The efficiency of
splenic macrophage depletion was verified histologically in spleens
from PBS- or L-Cl2MBP-treated mice at 3 days after
infection with WT virus. Frozen tissue sections were stained for
detection of macrophage-specific acid phosphatase (7), as
expression of this enzyme is minimally downregulated by MCMV infection
(59).
Cytokine analysis.
Levels of cytokines produced by
splenocytes in response to WT or mutant virus infections in mice with
intact spleens or macrophage-depleted spleens were compared. Mice were
injected i.v. with L-Cl2MBP or PBS and 48 h later were
infected i.v. with tissue culture-passaged virus as described above.
Spleens were harvested from three individual mice in each treatment
group at 36 h after infection, the time at which early cytokine
production in response to MCMV infection peaks (46).
Suspensions containing 5 × 106 total splenocytes per
ml were prepared in RPMI 1640 containing 1% low-endotoxin serum
(Hyclone) according to published procedures (37). After
24 h of culture, cell-free supernatants from each individual
spleen were pooled and frozen. Levels of TNF-
, IL-12 p40, IL-12 p70,
IFN-
, and IL-6 in the splenocyte-conditioned media were quantitated
by sandwich enzyme-linked immunosorbent assay (ELISA) as previously
described (6). Student's t test was performed to
evaluate statistical differences in cytokine values between mice
treated with L-Cl2MBP or PBS and between mice infected with
WT or mutant MCMV.
 |
RESULTS |
Construction and in vitro growth characteristics of RV10 and
RV10Rev.
We previously described a mutant MCMV, RV7, in which ORFs
m137 through M141, contained within the HindIII-J and -I
regions of the viral genome, are deleted and which grows poorly in the differentiated macrophage cell line IC-21 (2). Another
mutant virus, RV6, with m137 and m138 deleted, grows like WT virus in IC-21 macrophages (1), suggesting that an ORF(s) within the M139 to M141 region contributes to growth of MCMV in this cell type.
Therefore, a mutant virus (RV10) with ORFs M139, M140, and M141 deleted
was generated to assess the function of these ORFs in
macrophage-specific growth and viral pathogenesis. A marker-rescued revertant of RV10, RV10Rev, was also generated by homologous
recombination of WT sequences back into RV10. Southern blotting of
viral DNA digested with HindIII and BamHI
confirmed the genotypes of RV10 and RV10Rev (data not shown). Northern
blot analyses of RNA isolated from RV10-infected fibroblasts during the
late phase of replication revealed the expression of RNA transcripts of
WT size from genes proximal to the deleted region, although RV10 m138
RNA was larger than the RNA of WT virus. Transcripts from the
HindIII-J and -I region in RV10Rev-infected cells were
identical to those in WT virus-infected cells (data not shown).
Both RV10 and RV10Rev grew like WT virus in NIH 3T3 fibroblasts (Fig.
2A). Replicate experiments consistently
revealed no significant differences in growth among WT virus, RV10Rev,
and RV10 in this fibroblast cell line. These data confirm the
nonessential function of the M139 to M141 region in MCMV replication.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Growth of RV10 and WT MCMV in fibroblasts and
macrophages in vitro. Monolayers of NIH 3T3 cells (A) or IC-21
macrophages (B) were infected at a multiplicity of 0.1 PFU/cell.
Cell-free and cell-associated viruses were collectively titerate at the
indicated times postinfection by plaque assay on NIH 3T3 cells. Data
shown are representative of three individual experiments.
|
|
In contrast, growth characteristics of RV10 in differentiated, mature
macrophages proved that deletion of these three ORFs compromised the
ability of MCMV to grow in macrophages. Growth of RV10 in immortalized
IC-21 macrophages was significantly reduced, with peak titers up to
1,000-fold lower than that of WT virus or RV10Rev (Fig. 2B). Likewise,
peak titers of RV10 replication in primary, differentiated peritoneal
macrophages obtained by lavage were 100- and 500-fold lower than those
of WT virus at days 3 and 5 postinfection, respectively (data not
shown). In the primary macrophages, growth of RV6 was similar to that
of WT virus (data not shown), as previously reported for the IC-21 macrophage cell line (2). Thus, M139, M140, and/or M141 gene products are necessary for optimal growth of MCMV in differentiated macrophages. Importantly, the defect in growth of RV10 in the peritoneal macrophage cell line was reproducible in primary,
differentiated peritoneal macrophages. This validates the use of the
IC-21 cell line for further characterization of this mutant virus and
confirms the biological relevance of this gene region in MCMV pathogenesis.
Viral gene expression in RV10-infected macrophages.
It was of
interest to identify the stage of the MCMV replication cycle at which
growth of RV10 in macrophages was curtailed. The growth rate of RV10 in
IC-21 macrophages was similar to that previously reported for the
mutant virus RV7, which lacks ORFs m137 through M141 (2).
The defect in growth of RV7 was identified as a block in expression of
the major immediate-early genes ie1, ie2, and ie3 (2).
Therefore, immediate-early gene expression in RV10-infected IC-21
macrophages was assessed and compared to that in RV10Rev-infected
cells. For these experiments, highly purified infectious virions
obtained by centrifugation through a sorbitol density gradient were
used for infection of fibroblasts and IC-21 macrophages. Experiments
were performed by using each of the two bands (40 to 50% interface and
50 to 60% interface) which contained most of the infectious virus and
which likely contained a majority of single-capsid, enveloped virus
(3). Equal amounts of RNA from equal numbers of infected
cells were analyzed by Northern blotting for expression of
immediate-early genes. Expression from two immediate-early gene regions
was assessed
the major immediate-early gene region in
HindIII-L (ie1, ie2, and ie3) and immediate-early genes
m142 and m143 in HindIII-I (12). These two
immediate-early gene regions have different kinetics of expression and
are therefore likely to be independently regulated (12).
The results indicated that the ie1, ie3, m142, and m143 genes were
expressed from RV10Rev and RV10 at comparable levels in NIH 3T3
fibroblasts 4 h after infection (Fig.
3). However, ie1, ie3, m142, and m143
gene expression in RV10-infected IC-21 macrophages was significantly
reduced compared to that in RV10Rev-infected macrophages and compared
to that in RV10-infected fibroblasts. From these experiments, it was
evident that RV10 was significantly limited in expression of at least
these two immediate-early gene regions upon infection of IC-21
macrophages. Therefore, the M139, M140, and M141 gene region influences
replication in this macrophage cell line at the earliest stages of
infection: attachment, penetration, uncoating, or immediate-early gene
expression.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Expression of RV10 and RV10Rev immediate-early genes in
fibroblasts and macrophages. NIH 3T3 fibroblasts or IC-21 macrophages
were mock infected (M) or were infected with RV10Rev (Rev) or RV10 at a
multiplicity of 1 PFU/cell. The virus inocula were purified virions
banding at the 40 to 50% sorbitol interface of a 20 to 70% sorbitol
gradient. Five micrograms of total RNA harvested at 4 h after
infection was run on a formaldehyde gel for Northern blot analyses. The
loading of equal amounts of RNA was confirmed by ethidium bromide
staining of the 18S and 28S rRNA. (A) Analysis of the major
immediate-early gene region. The Northern blot was hybridized to a
probe corresponding to the HindIII L region of MCMV in
order to detect RNA from ie1 (2.7 kb), ie2 (1.7 kb), or ie3 (2.7 kb).
(B) Analysis of the m142 and m143 immediate-early gene region. The
Northern blot shown in panel A was stripped and hybridized with a probe
corresponding to m142 and m143 (bases 198832 to 201744 of the MCMV
genome) within HindIII-I. The faint band visible between
the m142 and m143 transcripts represents incompletely stripped ie1/ie3
signal.
|
|
Attachment and penetration of RV10 during infection of
macrophages.
The above-presented results indicated that expression
of at least two MCMV immediate-early gene regions in infected IC-21 macrophages was compromised by deletion of the M139 to M141 region. Because of these findings and the fact that M139, M140, and M141 are
expressed at early times after infection (12), we considered the possibility that these gene products influence entry of MCMV into
macrophages. It is possible that specific viral gene products are
required for efficient receptor-mediated attachment to and/or penetration into a phagocytic cell. Unfortunately, standard procedures to assess the rate of viral penetration could not be used because MCMV
does not form plaques in IC-21 cells. Therefore, we compared, by
Southern blotting, the amounts of macrophage-associated RV10 DNA and
RV10Rev DNA, representing attached and/or penetrated virus.
To confirm the validity of the assay as a measure of bound or
penetrated virus, we first compared results obtained by using Southern
blotting to those obtained by using the standard penetration assay in
NIH 3T3 fibroblasts (described in Material and Methods). Figure
4A depicts the rate of penetration of WT
MCMV into NIH 3T3 fibroblasts as measured by using a standard plaque
assay of infected monolayers subsequent to acid-glycine washes at
various time points to inactivate bound virus not yet penetrated. The results indicated that maximal penetration of MCMV into fibroblasts occurred between 60 and 90 min postinfection (after shift to 37°C). In a parallel experiment, NIH 3T3 fibroblasts infected with RV10Rev were harvested for Southern blotting at the indicated times after a
shift to 37°C. The results, shown in Fig. 4B, indicate that maximal
amounts of cell-associated virus stably bound or penetrated between 60 and 90 min postinfection. These results are identical to those obtained
by using the more-traditional penetration assay and verify that the
Southern blotting method is reliable for detecting DNA of
cell-associated virus that either is stably bound or has penetrated.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 4.
Wild-type MCMV and RV10Rev attachment to or penetration
into NIH 3T3 fibroblasts and IC-21 macrophages. (A) Penetration assay.
NIH 3T3 cells were infected with WT MCMV at room temperature for 1 h, were shifted to 37°C, and at the indicated times after the
temperature shift were washed with acid-glycine buffer. Monolayers were
then overlaid with semisolid complete medium and incubated for 5 days
to quantitate the number of plaques which formed in each treatment
group. The percentage of bound virus which penetrated was calculated as
follows: (the number of plaques formed with acid-glycine washing)/(the
number of plaques formed without acid-glycine washing) × 100. (B
and C) Viral DNA stably attached to or penetrated into fibroblasts and
macrophages. NIH 3T3 fibroblasts (B) or IC-21 macrophages (C) were
infected as described above at room temperature or at 4°C with
RV10Rev (4 PFU/cell). At the indicated times after the shift to 37°C,
monolayers were washed with acid-glycine buffer and returned for a
total of 4 h of incubation in complete medium. Cells were then
harvested for extraction of viral DNA and Southern blotting. The DNA
was hybridized with a probe corresponding to HindIII-L.
The C denotes control cells that were not washed with acid-glycine but
were incubated for a total of 4 h after the shift to 37°C.
|
|
When RV10Rev infection of IC-21 macrophages was assessed by the
Southern blotting method, maximal levels of viral DNA bound and/or
penetrated between 90 and 120 min postinfection (Fig. 4C). These data
suggest that entry of MCMV into macrophages is less efficient than
entry into fibroblasts. Nevertheless, by 120 min postinfection, maximal
amounts of WT MCMV attached to or penetrated into fibroblasts and IC-21 macrophages.
Based on the above-presented results, we compared the amounts of RV10
DNA and RV10Rev DNA associated with fibroblasts and macrophages at 120 min postinfection. Fibroblasts and IC-21 cells were infected with
either type of virus at a multiplicity of 4 PFU/cell at 4°C for
1 h and then shifted to 37°C. At 120 min after the shift,
monolayers were washed with acid-glycine buffer (except the controls)
and returned for incubation for a total of 4 h. Viral DNA was
harvested from the infected-cell monolayers and analyzed by Southern
blotting. The results, presented in Fig. 5, clearly show that comparable amounts
of RV10 DNA and RV10Rev DNA bound to or penetrated NIH 3T3 fibroblasts.
However, RV10 was much less efficient in either binding to or
penetrating IC-21 macrophages than RV10Rev. These results would explain
the lower levels of immediate-early gene expression upon RV10 infection of IC-21 cells.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 5.
RV10 attachment to or penetration into NIH 3T3
fibroblasts and IC-21 macrophages. Experiments were performed
essentially as described in the legend for Fig. 4B. In this experiment,
monolayers of NIH 3T3 fibroblasts or IC-21 macrophages were infected
with RV10 or RV10Rev (Rev), were shifted to 37°C, and at 120 min
after the shift were washed with acid-glycine buffer. Infected cells
were incubated for a total of 4 h in complete medium. Digestion of
RV10 DNA with HindIII and BamHI yields bands
of 2.8, 2.6, and 1.1 kb which hybridize to the HindIII-I
probe. RV10Rev DNA digested with the same enzymes yields bands of 4.1, 2.8, and 2.6 kb which hybridize to this probe.
|
|
Virulence of RV10 in SCID mice.
If macrophages are a prominent
target cell of MCMV infection in vivo, then a mutant virus that
replicates poorly in macrophages, such as RV10, is likely to be
attenuated for virulence in vivo. This phenotype would not be evident
in normal mice, such as BALB/c mice, because in these animals tissue
culture-passaged virus is highly attenuated. Stocks of virulent RV10
cannot be obtained because replication of this mutant virus was not
detectable in mouse salivary glands (52), as previously
shown for mutant virus RV7 (2). Therefore, we compared the
virulence of RV10 and RV10Rev in SCID mice. Because these mice are
devoid of mature, functional T and B lymphocytes, they are exquisitely
sensitive to MCMV infection, succumbing to as few as 3 PFU of tissue
culture-passaged virus (42). Thus, these mice provide
minimal control of MCMV replication within macrophages and other target
cell types. The numbers and function of tissue macrophages, which serve
as potential target cells, are normal in these otherwise
immunodeficient mice (1).
While all mice infected with 104 PFU of WT virus or RV10Rev
died by day 28 postinfection, all RV10-infected mice survived for at
least 90 days after infection (Fig. 6).
Infection with RV6, a mutant virus that grows like WT virus in
macrophages, also resulted in 100% mortality, although with delayed
kinetics compared to that produced by WT virus (Fig. 6B). From these
experiments, we conclude that the M139 to M141 gene region contributes
to MCMV virulence and pathogenesis in its natural host.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
Lethality of RV10 and WT MCMV for SCID mice. (A and B)
Mice (four or five per group) were infected i.p. with 104
PFU of the indicated virus and observed daily for mortality. The
experiments were performed twice.
|
|
Growth of RV10 in spleen and liver tissue.
The above-presented
data revealed a correlation between the virulence of MCMV and the
ability of the virus to replicate in macrophages. However, RV10 may be
replication defective for several cell types within target organs, and
in sum, these deficiencies contributed to its high degree of
attenuation in vivo. To test this hypothesis, we assessed the ability
of RV10 to replicate in two major target organs of BALB/c mice, the
spleen and liver. RV10 and RV10Rev were injected i.v. to directly
administer virus to these two target organs. The spleen contains a
dense network of macrophages in direct contact with the circulation.
The liver also contains an abundance of macrophages, but they are
diffusely distributed throughout the sinusoids. In addition,
hepatocytes are permissive for MCMV replication (39, 44).
The data shown in Fig. 7A indicate that
RV10 replicated poorly, if at all, in intact spleens on days 1 through
3 postinfection. Both RV10Rev and WT virus replicated substantially,
and RV6 (deleted of m137 and m138) replicated to modest levels in this
organ. No infectious WT or mutant viruses were detected in blood during the 3-day period (data not shown). The degree of MCMV replication in
the spleen correlated with lethality in SCID mice, suggesting that MCMV
replication in this organ is a major determinant of virus virulence in
vivo. In contrast to the spleen, RV10 replicated in liver tissue with
kinetics similar to that of WT virus and that of RV10Rev (Fig. 7B). The
attenuated virus RV6 also replicated with near-WT kinetics in this
organ. The data indicate that RV10 is not replication defective for all
tissues. The attenuated phenotype of RV10 appears to be restricted to
certain cell types in vivo.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 7.
Growth of RV10 and WT MCMV in spleen and liver tissues.
BALB/c mice were inoculated i.v. with 3 × 105 PFU of
the indicated virus. Spleen (A) and liver (B) tissues were harvested
from three individual mice at the indicated times postinfection. Virus
titers in 20% (wt/vol) tissue homogenates were determined by plaque
assay on NIH 3T3 cells. Data points are the average values for three
individual mice, and error bars represent standard deviations.
|
|
Growth of RV10 in macrophage-depleted tissues.
These data
suggested that the ability of MCMV to replicate in macrophages may
directly influence the level of virus replication in the
macrophage-dense environment of the spleen. Is growth of RV10 in
macrophages the limitation to replication in the spleen, or is RV10
replication defective for other cell types in this organ as well? In
order to demonstrate that splenic macrophages were the limitation to
efficient RV10 replication in this target organ, growth of RV10 in
intact spleens was compared to that in spleens specifically depleted of
tissue macrophages. Mice were depleted of splenic macrophages by i.v.
injection of L-Cl2MBP prior to MCMV infection with RV10 or
RV10Rev. This method is highly specific for depletion of macrophages
and macrophage-like dendritic cells, is nontoxic and, when
administration is i.v., is selective for spleen and liver macrophages
exclusively (see Materials and Methods). Virus titers in
macrophage-depleted spleens and livers were quantitated on days 1 to 3 postinfection and compared to those in control mice with intact organs.
As a control for L-Cl2MBP administration, PBS, rather than
empty liposomes, was chosen to ensure that control mice were normal
with respect to macrophage numbers and, importantly, with respect to
function as well (63). Histological examination of spleen
tissue collected from WT virus-infected mice 3 days postinfection
confirmed that L-Cl2MBP treatment was effective in
eliminating 80 to 90% of the acid phosphatase-positive marginal zone
and red pulp macrophages and in maintaining depletion of these cells
even after virus infection (Fig. 8).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 8.
Depletion of splenic macrophages by L-Cl2MBP
treatment. Frozen tissue sections of spleens from mice injected i.v.
with L-Cl2MBP (A) or PBS (B) and infected with 3 × 105 PFU of WT MCMV were stained for the macrophage-specific
marker acid phosphatase. Mice received virus 48 h after
L-Cl2MBP or PBS treatment, and spleens were harvested at 3 days postinfection. Acid phosphatase-positive cells in the red pulp,
marginal zone, and white pulp stain bright red.
|
|
Liposome treatment significantly enhanced levels of RV10Rev replication
in the spleen (Fig. 9A). More
dramatically, this treatment restored replication of RV10 from
undetectable levels of virus to greater than 104 PFU/ml of
spleen homogenate (Fig. 9A). These data indicate that red pulp
macrophages, marginal-zone macrophages, marginal-zone dendritic cells,
and possibly marginal metallophilic macrophages are cellular
determinants of early MCMV replication in the spleen. Most importantly,
the data indicate that in the absence of macrophages, RV10 is capable
of efficient replication in the spleen, thus suggesting that growth in
this cell type was indeed the limitation to replication of RV10 in this
organ. Depletion of Kupffer cells had a less dramatic effect on
replication of RV10Rev and RV10 in the liver (Fig. 9B). This supports
the evidence that other cells, such as hepatocytes, are a major target
cell type in this organ (39, 44) and indicates that RV10 is
not replication defective in such cells.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 9.
Growth of RV10 and WT MCMV in macrophage-depleted and
intact tissues. Mice were injected i.v. with either
L-Cl2MBP or PBS and 48 h later were infected with
3 × 105 PFU of the indicated virus. Spleens (A) and
livers (B) were harvested from four or five individual mice at the
indicated times postinfection. Virus titers in 20% (wt/vol)
homogenates were determined by plaque assay on NIH 3T3 cells. Data
points are the average values for individual mice, and error bars
represent standard deviations. Rev designates infection with RV10Rev,
the suffix -P designates treatment with PBS, and the suffix -L
designates treatment with L-Cl2MBP.
|
|
Antiviral cytokine response to RV10 and RV10Rev infection of the
spleen.
An explanation for the data presented above is that
splenic macrophages may be an initial target cell for MCMV replication and that in this cell type in vivo, production of WT virus may be
efficient yet limited while replication of RV10 is severely curtailed.
In the absence of such a macrophage filter, MCMV may have direct access
to more-permissive cell types that have not yet been identified.
However, there is an alternative explanation for the finding that MCMV
titers were higher in macrophage-depleted spleens. Macrophages are
likely a major source of antiviral cytokines and regulators of NK cell
activity early in MCMV infection (36, 37, 46). The antiviral
activity of cytokines and NK cells acting upon growth-retarded RV10 may
significantly inhibit mutant virus production, conferring the
attenuated phenotype in vivo. In the absence of macrophages and thus
the antiviral activity, perhaps RV10 has the opportunity to replicate
to substantial levels in other types of cells that normally support
only low levels of RV10 replication. If this hypothesis is correct,
then RV10 infection of intact spleens should induce levels of antiviral cytokines comparable to those induced by WT viruses in this organ. In
the absence of macrophages, RV10 should induce significantly lower
levels of cytokines.
We tested this hypothesis by comparing levels of cytokines in mock-,
RV10Rev-, or RV10-infected intact spleens with the levels in
L-Cl2MBP-treated spleens. We quantitated the levels of
IL-6, IL-12 (p40 and p70), and TNF-
, three cytokines produced early in response to MCMV infection (46). IFN-
was also
quantitated, as this potent antiviral cytokine is produced by
infiltrating NK cells in response to monokines induced by MCMV
infection (36). The results (see below) indicated that
enhanced replication of RV10 in macrophage-depleted spleens was not due
to a reduction in cytokine levels but more likely reflected the absence
of a macrophage barrier. Secondarily, the results revealed several interesting findings concerning the contribution of macrophages to
production of these cytokines and the influence of MCMVv's replicative
capacity on cytokine production. For clarity, the results are presented
below as follows: (i) comparison of cytokines induced by RV10Rev in
intact spleens with those in macrophage-depleted tissue, (ii)
comparison of cytokines induced in intact spleens by RV10 and by
RV10Rev, and (iii) comparison of cytokines induced by RV10 in intact
spleens and those in spleens depleted of macrophages.
In response to RV10Rev infection, splenocytes from intact organs
produced elevated levels of IL-6 (Fig.
10). However, the values were not
statistically different from those for mock-infected animals, and no
significant differences were found between normal and
macrophage-depleted spleens. Because there were no statistically significant differences among IL-6 levels in any of the six treatment groups, results of IL-6 determinations are not described below.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 10.
Cytokine levels produced by splenocytes in response to
RV10 or WT MCMV infection of normal or macrophage-depleted mice. Mice
were administered L-Cl2MBP (L) or PBS (P) i.v., and 48 h later, they were inoculated i.v. with mock virus preparation or with
RV10Rev or RV10 (3 × 105 PFU). Thirty-six hours
later, spleens were harvested from three individual mice, and
suspensions containing 5 × 106 splenocytes/ml were
incubated overnight. After 24 h, supernatants were collected and
cytokines were quantitated by sandwich ELISA assays. IL-12 data are for
IL-12 p40. Values represent the mean titers and error bars denote
standard deviations for three mice. A single asterisk denotes a
significant difference (P 0.05) between
L-Cl2MBP- and PBS-treated mice infected with RV10Rev. A
double asterisk denotes a significant difference (P 0.05) between RV10- and RV10Rev-infected mice treated with PBS.
The data are representative of two separate experiments.
|
|
As predicted, RV10Rev infection induced IL-12 p40 to detectable levels
(Fig. 10). Liposome treatment had no significant effect on production
of this cytokine, as levels of IL-12 p40 induced by RV10Rev in
PBS-treated or L-Cl2MBP-treated mice were not significantly different (P > 0.05). Therefore,
L-Cl2MBP-insensitive cells, such as endothelial cells, may
be a significant source of this cytokine following MCMV infection.
Levels of IL-12 p70 were, in general, undetectable (<1.0 pg/5 × 106 cells) in splenocyte-conditioned media from all
treatment groups (data not shown).
In contrast, production of the antiviral cytokines TNF-
and IFN-
was severely compromised by L-Cl2MBP treatment in
RV10Rev-infected animals (Fig. 10). At this early time postinfection
(36 h), TNF-
was likely produced by splenic macrophages, while
infiltrating, activated NK cells likely produced IFN-
. Apparently,
the production of IFN-
by NK cells and/or the infiltration of NK
cells was directly or indirectly compromised by L-Cl2MBP treatment.
A comparison of cytokine levels induced in intact spleens by infection
with RV10 and by infection with RV10Rev revealed that the replicative
capacity of MCMV influenced production of IL-12 p40, TNF-
, and
IFN-
. RV10, which fails to replicate to detectable levels in intact
spleens, induced significantly lower levels of these cytokines than did
RV10Rev (Fig. 10). This finding may reflect differences in the total
numbers of virus-infected cells and implies that virus replication per
se, rather than mere exposure to virions, was required for optimal
production of these early, antiviral cytokines.
Finally, a comparison of cytokine levels induced in PBS- and
L-Cl2MBP-treated mice infected with RV10 demonstrated that
L-Cl2MBP treatment had no significant effect on levels of
any of the four cytokines induced by this mutant virus. Importantly,
these data indicated that the enhancement of replication of RV10 in
macrophage-depleted spleens compared to that in intact organs was not
due to a reduction in levels of these cytokines. Thus, elevated titers
of RV10 in macrophage-depleted spleens likely reflected the absence of
a macrophage filter and increased access to more-permissive cell types.
 |
DISCUSSION |
Results of in vitro studies using mutant virus RV10 suggest that
the products of MCMV M139, M140, and/or M141 function to regulate
growth of this virus in macrophages, a biologically important target
cell. Mutant RV10 is impaired in the early stages of MCMV replication
in macrophages, i.e., at or preceding the time of viral immediate-early
gene expression. The levels of expression of at least four
immediate-early genes from two different regions of the MCMV genome,
HindIII-L and HindIII-I, were
significantly lower in RV10-infected macrophages than in
RV10Rev-infected cells. The results of experiments performed to
semiquantitatively assess the amount of virus stably bound to or
penetrated into macrophages indicate that the M139, M140, and/or M141
gene product likely functions in efficient MCMV attachment to or
penetration into macrophages. Products of M139, M140, or M141
apparently do not confer resistance to the antiviral effects of
IFN-
/
, which is produced early after infection of macrophages,
because neutralization of these type I interferons does not restore
growth of RV10 in IC-21 macrophages (52). Current studies
aim to (i) identify the gene(s) which bestows efficient replication of
MCMV in macrophages, (ii) characterize the gene product(s), and (iii)
assess the function of the gene product(s) in specific stages of MCMV
entry into macrophages or as a transcriptional transactivator of
immediate-early genes.
Through the use of RV10 and L-Cl2MBP, several interesting
yet paradoxical findings concerning the role of tissue macrophages in
MCMV pathogenesis were obtained. The fact that RV10 was defective for
growth in macrophages in vitro and in spleen tissue in vivo supports
the notion that efficient replication of MCMV in macrophages is
required for abundant growth in at least this target organ. This cell
type provided the limitation to RV10 replication in the spleen, as RV10
grew to nearly WT levels in macrophage-depleted spleens. The data on
MCMV replication in L-Cl2MBP-treated compared to
PBS-treated spleens, however, clearly demonstrate that splenic marginal-zone macrophages, marginal metallophilic macrophages, red pulp
macrophages, and marginal-zone dendritic cells are not required for
replication of MCMV in the spleen. In contrast, these cells provide a
net protective effect.
The fact that efficient replication of MCMV in macrophages appeared to
be a prerequisite for virus replication in the spleen even though
macrophage and dendritic cell depletion enhanced virus growth seems
paradoxical. However, this may be explained by the concept of
macrophages/dendritic cells serving as a protective barrier or filter.
In the spleen, macrophages are likely one of the first cell types
exposed to blood-borne virus. The abilities of macrophages to (i)
destroy, through phagocytosis, a percentage of extracellular virions,
(ii) produce antiviral cytokines, and (iii) regulate growth of HCMV
(8, 9, 25) or MCMV (17, 66) which enters
macrophages via receptor-mediated events collectively may confer their
protective function. Consequently, the ability of MCMV to replicate
efficiently in this cell type and subsequently seed neighboring,
perhaps more-permissive cell types may ultimately determine virus
titers in the spleen.
Our data indicate that macrophages contribute directly or indirectly to
production of two cytokines, TNF-
and IFN-
, both of which inhibit
MCMV replication (17, 28). The latter cytokine is produced
early in MCMV infection by activated NK cells (38). Indeed,
independent studies have shown that L-Cl2MBP treatment of
C57BL/6 mice prior to MCMV infection eliminated NK cell infiltration in
the spleen, as assessed by quantitation of NK1.1+ and/or
DX5+ CD3
splenocytes and by killing of
NK-sensitive YAC-1 cells (45). This is likely due to a
dependence of NK cell infiltration, differentiation, or activation on
cytokines or chemokines produced by macrophages or marginal-zone
dendritic cells (47, 48). For example, Kupffer cells are
required for the differentiation of peripheral blood NK cells into
highly activated, hepatic NK cells (60).
Comparisons between the cytokine profiles of macrophage-depleted
spleens and intact spleens from mice infected with RV10 indicate that
differences in cytokine production cannot explain the restored growth
of RV10 in macrophage-depleted animals. There were no significant differences between the two treatment groups for RV10-induced IL-6,
IL-12, IFN-
, or TNF-
levels. Although we cannot rule out the
possibility that the levels of other antiviral cytokines induced by
RV10 but not quantitated in this study were diminished by macrophage depletion, we conclude that the elimination of macrophages as a target
cell for RV10 had the greatest influence on RV10 replication in the spleen.
The ability of MCMV to replicate in the spleen appeared to influence
the overall degree of virulence, an observation previously reported
(19). In this study, a direct correlation between the ability of MCMV to replicate in the spleen and lethality in SCID mice
was noted. RV6, which replicated in the spleen but replicated poorly
compared to WT virus or RV10Rev, killed SCID mice with delayed
kinetics. We have found that other mutant MCMV which replicate in the
spleen, but only poorly compared to WT virus, kill SCID mice with
delayed kinetics (13). RV10, which failed to replicate to
detectable levels in the spleen, did not kill SCID mice within 90 to
100 days. It is not feasible to repeat the lethality studies using
L-Cl2MBP-treated SCID mice, as most all macrophage
subpopulations in the spleen would be restored after
L-Cl2MBP treatment by the expected time of MCMV-induced
death (62), and effects of repeated L-Cl2MBP
injections have not been assessed in this immunocompromised host.
Macrophages had a minor role in control of MCMV replication in the
liver compared to that of replication in the spleen. The mutant virus
RV10, which failed to replicate to detectable levels in the spleen,
replicated to WT levels in the liver. Depletion of Kupffer cells
enhanced levels of MCMV replication in the liver, but to a lesser
extent than in the spleen. The liver contains large numbers of tissue
macrophages, diffusely distributed throughout the sinusoids, in
contrast to the highly organized, dense network of splenic macrophages.
Aside from this anatomical difference, the quality or function of
tissue macrophages residing in the liver and spleen may differ. For
example, the peaks of the titers of type I interferons are delayed and
the titers are significantly lower in the livers of MCMV-infected
BALB/c mice compared to those in the spleen (67). Other
antiviral immune effector cells, such as NK cells, function divergently
in these two organs (57). Furthermore, there is evidence
that in the liver, hepatocytes are the preferred target cell for MCMV
replication (39, 44). Collectively, these differences
between the liver and the spleen may explain the tissue-specific
discrepancies in RV10 replication and in the effect of
L-Cl2MBP treatment on MCMV replication in these tissues.
The results of these studies support the hypothesis that macrophages
play a pivotal role in the pathogenesis of MCMV infections. Initially,
these cells may serve as target cells in at least the spleen, and the
capacity of the virus to replicate efficiently in macrophages
influences, in part, the magnitude of MCMV replication in that organ.
While efficient replication in macrophages may be a necessary (although
not sufficient) requirement for robust virus replication in this
important target organ, MCMV replication in this cell type leads to
controlled growth of the virus, likely due collectively to the growth
rate of the virus in this cell type and the early induction of
antiviral cytokines. These two conditions may provide a net protective
role for at least splenic macrophages and may favor the eventual
establishment of MCMV latency in macrophages. It is likely that complex
virus-macrophage interactions which are beneficial to both the virus
and the host exist, ensuring persistence of CMV within the host.
 |
ADDENDUM |
A recent study using L-Cl2MBP-treated mice also
revealed a protective role for tissue macrophages during the early
stages of acute MCMV infection (S. Hamano, H. Yoshida, H. Takimoto, K. Sonoda, K. Osada, X. He, Y. Minamishima, G. Kimura, and K. Nomoto, Microbiol. Immunol. 42:607-616, 1998).
 |
ACKNOWLEDGMENTS |
This work was supported by PHS grant R01 CA41451 (to A.E.C. and
R.M.S.) and by The Thomas F. Jeffress and Kate Miller Jeffress Memorial
Trust (A.E.C.). H.W.V. was supported by PHS grant R01 AI39616. C.A.B.
and M.C.R. were supported by PHS grants R01 MH47674 and T32 ES07272, respectively.
We sincerely thank Boehringer Mannheim for the generous contribution of
dichloroimethylene-bisphosphonate. We appreciate the critical review of
the manuscript by Victoria J. Cavanaugh.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Molecular Cell Biology, Eastern Virginia Medical
School, P.O. Box 1980, 700 W. Olney Rd., Norfolk, VA 23507. Phone:
(757) 446-5667. Fax: (757) 624-2255. E-mail:
campbeae{at}evms.edu.
 |
REFERENCES |
| 1.
|
Bancroft, G. J., and J. P. Kelly.
1994.
Macrophage activation and innate resistance to infection in SCID mice.
Immunobiology
191:424-431[Medline].
|
| 2.
|
Cavanaugh, V. J.,
R. M. Stenberg,
T. L. Staley,
H. W. Virgin IV,
M. R. MacDonald,
S. Paetzold,
H. E. Farrell,
W. D. Rawlinson, and A. E. Campbell.
1996.
Murine cytomegalovirus with a deletion of genes spanning HindIII-J and -I displays altered cell and tissue tropism.
J. Virol.
70:1365-1374[Abstract].
|
| 3.
|
Chong, K. T., and C. A. Mims.
1981.
Murine cytomegalovirus particle types in relation to sources of virus and pathogenicity.
J. Gen. Virol.
57:415-419[Abstract/Free Full Text].
|
| 4.
|
Collins, T. M.,
M. R. Quirk, and M. C. Jordon.
1994.
Biphasic viremia and viral gene expression in leukocytes during acute cytomegalovirus infection of mice.
J. Virol.
68:6305-6311[Abstract/Free Full Text].
|
| 5.
|
Compton, T.,
D. M. Nowlin, and N. R. Cooper.
1993.
Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate.
Virology
193:834-841[Medline].
|
| 6.
|
Cousens, L. P.,
J. S. Orange,
H. C. Su, and C. A. Biron.
1997.
Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection.
Proc. Natl. Acad. Sci. USA
94:634-639[Abstract/Free Full Text].
|
| 7.
|
Eikelenboom, P.
1978.
Characterization of non-lymphoid cells in the white pulp of the mouse spleen: an in vivo and in vitro study.
Cell Tissue Res.
195:445-460[Medline].
|
| 8.
|
Fish, K. N.,
W. Britt, and J. A. Nelson.
1996.
A novel mechanism for persistence of human cytomegalovirus in macrophages.
J. Virol.
70:1855-1862[Abstract].
|
| 9.
|
Fish, K. N.,
A. S. Depto,
A. V. Moses,
W. Britt, and J. A. Nelson.
1995.
Growth kinetics of human cytomegalovirus are altered in monocyte-derived macrophages.
J. Virol.
69:3737-3743[Abstract].
|
| 10.
|
Gribaudo, G.,
S. Ravaglia,
M. Gaboli,
M. Gariglio,
R. Cavallo, and S. Landolfo.
1995.
Interferon-alpha inhibits the murine cytomegalovirus immediate-early gene expression by down-regulating NF- activity.
Virology
211:251-260[Medline].
|
| 11.
|
Hahn, G.,
R. Jores, and E. S. Mocarski.
1998.
Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells.
Proc. Natl. Acad. Sci. USA
95:3937-3942[Abstract/Free Full Text].
|
| 12.
| Hanson, L. K., B. L. Dalton, Z. Karabekian,
H. E. Farrell, W. D. Rawlinson, R. M. Stenberg, and
A. E. Campbell. Transcriptional analysis of the murine
cytomegalovirus HindIII-I region: identification of a
novel immediate early gene region. Submitted for publication.
|
| 13.
| Hanson, L. K., J. S. Slater, H. W. Virgin
IV, and A. E. Campbell. Unpublished data.
|
| 14.
|
He, X.,
H. Yoshida,
Y. Minamishima, and K. Nomoto.
1995.
Analysis of the role of CD4+ T-cells during murine cytomegalovirus infection in different strains of mice.
Virus Res.
36:233-245[Medline].
|
| 15.
|
Heise, M. T.,
M. Connick, and H. W. Virgin, IV.
1998.
Murine cytomegalovirus inhibits interferon gamma-induced antigen presentation to CD4 T cells by macrophages via regulation of expression of major histocompatibility complex class II-associated genes.
J. Exp. Med.
187:1037-1046[Abstract/Free Full Text].
|
| 16.
|
Heise, M. T.,
J. L. Pollock,
A. O'Guin,
M. L. Barkon,
S. Bormley, and H. W. Virgin, IV.
1998.
Murine cytomegalovirus infection inhibits IFN gamma-induced MHC class II expression on macrophages: the role of type I interferon.
Virology
241:331-344[Medline].
|
| 17.
|
Heise, M. T., and H. W. Virgin, IV.
1995.
The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections.
J. Virol.
69:904-909[Abstract].
|
| 18.
|
Ibanez, C. E.,
R. Schrier,
P. Ghazal,
C. Wiley, and J. A. Nelson.
1991.
Human cytomegalovirus productively infects primary differentiated macrophages.
J. Virol.
65:6581-6588[Abstract/Free Full Text].
|
| 19.
|
Katzenstein, D. A.,
G. S. Yu, and M. C. Jordan.
1983.
Lethal infection with murine cytomegalovirus after early viral replication in the spleen.
J. Infect. Dis.
148:406-411[Medline].
|
| 20.
|
Koffron, A. J.,
J. Hummel,
B. K. Patterson,
S. Yan,
D. B. Kaufman,
J. P. Fryer,
F. P. Stuart, and M. I. Abecassis.
1998.
Cellular localization of latent murine cytomegalovirus.
J. Virol.
72:95-103[Abstract/Free Full Text].
|
| 21.
|
Kohler, C. P.,
J. A. Kerry,
M. Carter,
V. P. Muzithras,
T. R. Jones, and R. M. Stenberg.
1994.
Use of recombinant virus to assess human cytomegalovirus early and late promoters in the context of the viral genome.
J. Virol.
68:6589-6597[Abstract/Free Full Text].
|
| 22.
|
Kondo, K.,
J. Xu, and E. S. Mocarski.
1996.
Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals.
Proc. Natl. Acad. Sci. USA
93:11137-11142[Abstract/Free Full Text].
|
| 23.
|
Koszinowski, U. H.,
M. Del Val, and M. J. Reddehase.
1990.
Cellular and molecular basis of the protective immune response to cytomegalovirus infection.
Curr. Top. Microbiol. Immunol.
154:189-220[Medline].
|
| 24.
|
Larsson, S.,
C. Soderberg-Naucler,
F. Z. Wang, and E. Moller.
1998.
Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time.
Transfusion (Bethesda)
38:271-278.
[Medline] |
| 25.
|
Lathey, J. L., and S. A. Spector.
1991.
Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages.
J. Virol.
65:6371-6375[Abstract/Free Full Text].
|
| 26.
|
Leenen, P. J.,
K. Radosevic,
J. S. Voerman,
B. Salomon,
N. van Rooijen,
D. Klatzmann, and W. van Ewijk.
1998.
Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover.
J. Immunol.
160:2166-2173[Abstract/Free Full Text].
|
| 27.
|
Long, D.,
G. H. Cohen,
M. I. Muggeridge, and R. J. Eisenberg.
1990.
Cysteine mutants of herpes simplex virus type 1 glycoprotein D exhibit temperature-sensitive properties in structure and function.
J. Virol.
64:5542-5552[Abstract/Free Full Text].
|
| 28.
|
Lucin, P.,
S. Jonjic,
M. Messerle,
B. Polic,
H. Hengel, and U. H. Koszinowski.
1994.
Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor.
J. Gen. Virol.
75:101-110[Abstract/Free Full Text].
|
| 29.
|
Maciejewski, J. P.,
E. E. Bruening,
R. E. Donahue,
S. E. Sellers,
C. Carter,
N. S. Young, and S. St. Jeor.
1993.
Infection of mononucleated phagocytes with human cytomegalovirus.
Virology
195:327-336[Medline].
|
| 30.
|
Mauel, J., and V. Defendi.
1971.
Infection and transformation of mouse peritoneal macrophages by simian virus 40.
J. Exp. Med.
134:335-350[Abstract].
|
| 31.
|
Mendelson, M.,
S. Monard,
P. Sissons, and J. Sinclair.
1996.
Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors.
J. Gen. Virol.
77:3099-3102[Abstract/Free Full Text].
|
| 32.
|
Michelson, S.
1997.
Interaction of human cytomegalovirus with monocytes/macrophages: a love-hate relationship.
Pathol. Biol.
45:146-158[Medline].
|
| 33.
|
Minton, E. J.,
C. Tysoe,
J. H. Sinclair, and J. G. P. Sissons.
1994.
Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow.
J. Virol.
68:4017-4021[Abstract/Free Full Text].
|
| 34.
|
Mitchell, B. M.,
A. Leung, and J. G. Stevens.
1996.
Murine cytomegalovirus DNA in peripheral blood of latently infected mice is detectable only in monocytes and polymorphonuclear leukocytes.
Virology
223:198-207[Medline].
|
| 35.
|
Naito, M.,
H. Nagaie,
S. Kawano,
H. Umeza,
H. Zhu,
H. Moriyama,
T. Yamamoto,
H. Takahashi, and Y. Takei.
1996.
Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro.
J. Leukoc. Biol.
60:337-344[Abstract].
|
| 36.
|
Orange, J. S., and C. A. Biron.
1996.
An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections.
J. Immunol.
156:1138-1142[Abstract].
|
|